Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Otto, Claudia ^a   Csanadi, Agnes ^a   Fisch, Paul ^a   Werner, Martin ^a   Kayser, Gian ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEAR PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

AGED; ARTICLE; CASE REPORT; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVATION; ENZYMOLOGY; EXON; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; ENZYME ACTIVATION; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MODELS, MOLECULAR; MUTAGENESIS, INSERTIONAL; NUCLEAR PROTEINS; PHENOTYPE; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867638024     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-146     Document Type: Article

References (30)

1. Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Eng J Med 2005, 352(20):2136. author reply 2136.
2. Uruga H, Kishi K, Fujii T, Beika Y, Enomoto T, Takaya H, Miyamoto A, Morokawa N, Kurosaki A, Yoshimura K. Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med 2010, 49(2):103-107. 10.2169/internalmedicine.49.2531, 20075572.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Eng J Med 2010, 362(25):2380-2388.
4. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 2002, 7(Suppl 4):31-39.
5. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl 1):S24-S31. 2849651, 19680293.
6. Kayser G, Sienel W, Kubitz B, Mattern D, Stickeler E, Passlick B, Werner M, Zur Hausen A. Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology 2011, 43(7):719-724. 10.1097/PAT.0b013e32834c352b, 22027741.
7. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346. 10.1093/jnci/dji055, 15741570.
8. Shigematsu H, Gazdar AF. Mutations of EGFR in lung cancers and their implications for targeted therapy. Discov Med 2004, 4(24):444-447.
9. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer & Journal International Du Cancer 2006, 118(2):257-262.
10. He M, Capelletti M, Nafa K, Yun CH, Arcila ME, Miller VA, Ginsberg MS, Zhao B, Kris MG, Eck MJ, et al. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clinical Can Res 2012, 18(6):1790-1797.
11. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, Delmonte A, Giovannini M, Spaggiari L, de Braud F, et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. Journal of Thoracic Oncology 2011, 6(11):1895-1901. 10.1097/JTO.0b013e318227e8c6, 21841502.
12. Ilie MI, Hofman V, Bonnetaud C, Havet K, Lespinet-Fabre V, Coelle C, Gavric-Tanga V, Venissac N, Mouroux J, Hofman P. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Archiv 2010, 457(4):483-495. 10.1007/s00428-010-0963-z, 20803030.
13. Job B, Bernheim A, Beau-Faller M, Camilleri-Broet S, Girard P, Hofman P, Mazieres J, Toujani S, Lacroix L, Laffaire J, et al. Genomic aberrations in lung adenocarcinoma in never smokers. PLoS One 2010, 5(12):e15145. 10.1371/journal.pone.0015145, 2997777, 21151896.
14. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004, 64(24):8919-8923. 10.1158/0008-5472.CAN-04-2818, 15604253.
15. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005, 23(11):2513-2520. 10.1200/JCO.2005.00.992, 15738541.
16. Okami J, Taniguchi K, Higashiyama M, Maeda J, Oda K, Orita N, Koizumi K, Kodama K, Kato K. Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer. Oncology 2007, 72(3-4):234-242.
17. Yoshida Y, Shibata T, Kokubu A, Tsuta K, Matsuno Y, Kanai Y, Asamura H, Tsuchiya R, Hirohashi S. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005, 50(1):1-8. 10.1016/j.lungcan.2005.04.012, 15950315.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Eng J Med 2004, 350(21):2129-2139.
19. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 2006, 22(2):195-201. 10.1093/bioinformatics/bti770, 16301204.
20. Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. The SWISS-MODEL Repository and associated resources. Nucleic Acids Res 2009, 37(Database issue):D387-D392. 2686475, 18931379.
21. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008, 26(10):1742-1751. 10.1200/JCO.2007.12.1178, 18375904.
22. Yang W. Structure and mechanism for DNA lesion recognition. Cell Res 2008, 18(1):184-197. 10.1038/cr.2007.116, 18157156.
23. Casorzo L, Corigliano M, Ferrero P, Venesio T, Risio M. Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. Diagn Pathol 2009, 4:36. 10.1186/1746-1596-4-36, 2781797, 19889201.
24. Shen S, Qin D. Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis. Diagn Pathol 2012, 7:56. 10.1186/1746-1596-7-56, 3433338, 22640803.
25. Fassina A, Gazziero A, Zardo D, Corradin M, Aldighieri E, Rossi GP. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis. J Clin Pathol 2009, 62(12):1096-1102. 10.1136/jcp.2009.067587, 19640859.
26. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009, 63(3):315-321. 10.1016/j.lungcan.2008.06.021, 18760859.
27. Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008, 8:142. 10.1186/1471-2407-8-142, 2408599, 18495026.
28. Raz DJ, Jablons DM. EGFR expression and mutational analysis as a predictive test. J Clin Oncol 2007, 25(15):2144-2145.
29. Daniele L, Macri L, Schena M, Dongiovanni D, Bonello L, Armando E, Ciuffreda L, Bertetto O, Bussolati G, Sapino A. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol Cancer Ther 2007, 6(4):1223-1229. 10.1158/1535-7163.MCT-06-0719, 17406029.
30. Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Archiv 2005, 446(5):483-488. 10.1007/s00428-005-1254-y, 15815931.